Table 3.
Characteristics of the vertically infected group at enrolment and after 18 months of follow-up (N = 731)
| <2 years | 2–4 years | 5–10 years | 11–21 years | Total | |
|---|---|---|---|---|---|
| Characteristics | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) |
| Gender | |||||
| Female | 47 (58.8) | 117 (51.8) | 180 (55.7) | 62 (60.8) | 406 (55.5) |
| Male | 33 (41.2) | 109 (48.2) | 143 (44.3) | 40 (39.2) | 325 (44.5) |
| ARV received by mother during pregnancy | |||||
| Yes | 30 (39.0) | 30 (14.9) | 20 (7.6) | 0 (0.0) | 80 (13.1) |
| No | 47 (61.0) | 171 (85.1) | 242 (92.4) | 72 (100) | 532 (86.9) |
| Unknown | 3 | 25 | 61 | 30 | 119 |
| HIV RNA copies/ml at enrolment | |||||
| <500 | 17 (21.8) | 60 (26.9) | 100 (31.0) | 33 (32.4) | 210 (28.9) |
| 500–9999 | 15 (19.2) | 45 (20.2) | 93 (28.8) | 31 (30.4) | 184 (25.3) |
| 10 000–99 999 | 15 (19.2) | 79 (35.4) | 105 (32.5) | 33 (32.4) | 232 (32.0) |
| ≥100 000 | 31 (39.7) | 39 (17.5) | 25 (7.7) | 5 (4.9) | 100 (13.8) |
| Missing | 2 | 3 | 0 | 0 | 5 |
| HIV RNA copies/ml at 18 months | |||||
| <500 | 20 (37.7) | 67 (37.6) | 115 (36.9) | 41 (40.2) | 243 (37.7) |
| 500–9999 | 11 (20.8) | 44 (24.7) | 99 (31.7) | 31 (30.4) | 185 (28.7) |
| 10 000–99 999 | 16 (30.2) | 53 (29.8) | 80 (25.6) | 26 (25.5) | 175 (27.1) |
| ≥100 000 | 6 (11.3) | 14 (7.9) | 18 (5.8) | 4 (3.9) | 42 (6.5) |
| Missing | 27 | 48 | 11 | 0 | 86 |
| CD4% results at enrolment | |||||
| <15% | 9 (12.2) | 23 (11.6) | 29 (10.4) | 13 (14.0) | 74 (11.5) |
| 15–24% | 19 (25.7) | 54 (27.3) | 73 (26.1) | 41 (44.1) | 187 (29.0) |
| ≥25% | 46 (62.2) | 121 (61.1) | 178 (63.6) | 39 (41.9) | 384 (59.5) |
| Missing | 6 | 28 | 43 | 9 | 86 |
| CD4% results at 18 months | |||||
| <15% | 2 (3.8) | 7 (4.0) | 24 (8.1) | 15 (15.5) | 48 (7.8) |
| 15–24% | 9 (17.0) | 36 (20.8) | 80 (27.1) | 36 (37.1) | 161 (26.1) |
| ≥25% | 42 (79.2) | 130 (75.1) | 191 (64.7) | 46 (47.4) | 409 (66.2) |
| Missing | 27 | 53 | 28 | 5 | 113 |
| CDC Clinical Classification at enrolment | |||||
| C | 22 (31.0) | 82 (36.3) | 102 (31.6) | 27 (26.5) | 233 (32.3) |
| B | 13 (18.3) | 67 (29.6) | 112 (34.7) | 41 (40.2) | 233 (32.3) |
| A/N | 36 (50.7) | 77 (34.1) | 109 (33.7) | 34 (33.3) | 256 (35.5) |
| Missing | 9 | 0 | 0 | 0 | 9 |
| CDC clinical classification at 18 months | |||||
| C | 26 (32.5) | 85 (37.6) | 103 (31.9) | 29 (28.4) | 243 (33.2) |
| B | 21 (26.3) | 69 (30.5) | 118 (36.5) | 41 (40.2) | 249 (34.1) |
| A/N | 33 (41.3) | 72 (31.9) | 102 (31.6) | 32 (31.4) | 239 (32.7) |
| Child's ARV regimen at enrolment | |||||
| No ARV | 35 (43.8) | 49 (21.7) | 29 (9.0) | 5 (4.9) | 118 (16.1) |
| NRTI-based only | 12 (15.0) | 27 (11.9) | 65 (20.1) | 24 (23.5) | 128 (17.5) |
| PI-based HAART | 28 (35.0) | 107 (47.3) | 146 (45.2) | 45 (44.1) | 326 (44.6) |
| NNRTI-based HAART | 5 (6.3) | 33 (14.6) | 51 (15.8) | 13 (12.7) | 102 (14.0) |
| PI + NNRTI-based HAART | 0 (0.0) | 10 (4.4) | 31 (9.6) | 14 (13.7) | 55 (7.5) |
| Other | 0 (0.0) | 0 (0.0) | 1 (0.3) | 1 (1.0) | 2 (0.3) |
| Type of ARV regimen received at 18 months | |||||
| No ARV | 8 (14.5) | 26 (14.6) | 15 (4.8) | 6 (5.9) | 55 (8.5) |
| NRTI-based only | 9 (16.4) | 21 (11.8) | 54 (17.1) | 19 (18.6) | 103 (15.8) |
| PI-based HAART | 32 (58.2) | 89 (50.0) | 156 (49.5) | 48 (47.1) | 325 (50.0) |
| NNRTI-based HAART | 6 (10.9) | 34 (19.1) | 64 (20.3) | 18 (17.6) | 122 (18.8) |
| PI + NNRTI-based HAART | 0 (0.0) | 8 (4.5) | 26 (8.3) | 11 (10.8) | 45 (6.9) |
| Missing | 25 | 48 | 8 | 0 | 81 |